Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. An email was sent with password retrieval instructions. Backtested performance is not an indicator of future actual results. Cookies are used to offer you a better browsing experience and to analyze our traffic. SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. These statements include statements regarding Codex DNAs future financial performance, growth of operations and customer base, progress made on achieving corporate goals, and the future release and success of products and services. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. Other expense increases were related to professional services, R&D material costs, facility costs, and insurance costs. These statements include statements and guidance regarding Codex DNAs future financial performance as well as statements regarding the future release and success of products and services. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Condensed Consolidated Balance Sheet (Parenthetical), Condensed Consolidated Statements Of Cash Flows, Condensed Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (Deficit), Condensed Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical), Condensed Consolidated Statements Of Operations And Comprehensive Loss, Fair Value Measurement - Assets And Liabilities (Details), Fair Value Measurement - Narrative (Details), Fair Value Measurement - Quantitative Inputs (Details), Fair Value Measurement - Roll Forward Of Level 3 Financial Instruments (Details), Goodwill And Other Intangible Assets (Tables), Goodwill And Other Intangible Assets - Narrative (Details), Goodwill And Other Intangible Assets - Schedule Of Amortization Expense (Details), Leases - Components Of Lease Cost (Details), Leases - Minimum Future Lease Payments (Details), Leases - Weighted-Average Lease Terms And Interest Rates (Details), Net Loss Per Share - Antidilutive Securities (Details), Net Loss Per Share - Basic And Diluted Earnings Per Share (Details), Notes Payable - Schedule Of Long-Term Debt (Details), Notes Payable - Schedule Of Maturities (Details), Property And Equipment - Narrative (Details), Property And Equipment - Schedule Of Property And Equipment (Details), Stock-Based Compensation - Classification Of Expense (Details), Stock-Based Compensation - Fair Value Assumptions (Details), Stock-Based Compensation - Narrative (Details), Stock-Based Compensation - Stock Option Activity (Details), Summary Of Significant Accounting Policies, Summary Of Significant Accounting Policies (Details), Summary Of Significant Accounting Policies (Policies), Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/dnay/0001850079-21-000041.htm. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Recent Highlights Continued execution across all areas of the growth strategy: For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate., Invest Like a Pro with Unique Data & Simplifed Tools. Updated 2022 Financial Guidance Please log in approximately 5-10 minutes before the event to ensure a timely connection. Richard Lepke Please log in approximately 5-10 minutes before the event to ensure a timely connection. Richard Lepke The archived webcast will remain available for replay on Codex DNAs website for 30 days. These financial results reflect the strong underlying momentum that has been building over the last year and better position the company for long-term success. Revenue was $5.7 million for the second quarter 2022, a 98% increase from $2.9 million for the same period in the prior year. The conference call can be accessed by dialing (888) 705-0127 (domestic) or +1 (409) 937-8880 (international) and referring to conference ID 7942349. Codex DNA Reports Second Quarter 2022 Financial Results Published: Aug 09, 2022 SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. The press release and live audio webcast can be accessed via the Investor section of Codex DNAs website at www.codexdna.com. This growth was driven by sales of BioXp 3250 instruments and kits and services. The press release and live audio webcast can be accessed via the Investor section of the Companys website at www.codexdna.com. Certain assumptions have been made for modeling purposes and are unlikely to be realized. Recent HighlightsContinued to execute in all areas of our growth strategy: Advanced our research and development programs: Webcast and Conference Call InformationCompany management will host a conference call today,Tuesday, May 10, 2022, at1:30 p.m. PDT/4:30 p.m. EDT to discuss the financial results and other recent corporate highlights. In the first quarter of 2022, we delivered robust revenue growth across our product portfolio, said Todd R. Nelson, PhD, CEO of Codex DNA. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. BioXp 3250 sales of 16 instruments, which was up 23% over the same period in the prior year. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-Looking StatementsThis press release contains forward-looking statements. Royalties and other revenue grew at 113% over second quarter 2021 due to revenue from the collaboration with Pfizer and continued growth of in-licensing royalties. The increase of $1.9 million was primarily driven by increased sales, resulting in higher raw material costs associated with reagents sales and biofoundry services, shipping and logistics costs, and increased personnel and departmental expenses. 10-K Annual . SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, 2022. Codex DNA disclaims any obligation to update these forward-looking statements. Codex DNA Reports Third Quarter 2021 Financial Results GlobeNewswire SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) Codex DNA, Inc. ( Nasdaq: DNAY ), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. The increase of $1.9 million was primarily driven by increased sales, resulting in higher raw material costs associated with reagents sales and biofoundry services, shipping and logistics costs, and increased personnel and departmental expenses. For the full year 2022, Codex DNA provided the following updated financial guidance: Webcast and Conference Call InformationCompany management will host a conference call today, August 9, 2022, at1:30 p.m. PDT/4:30 p.m. EDT to discuss the financial results and other recent corporate highlights. Total revenue in the range of$22million to$24 million, up from prior guidance of $19 million to $21 million. These statements include statements regarding Codex DNAs future financial performance, growth of operations and customer base, progress made on achieving corporate goals, and the future release and success of products and services. Company management will host a conference call today, Tuesday, May 10, 2022, at 1:30 p.m. PDT / 4:30 p.m. EDT to discuss the financial results and other recent corporate highlights. We continue to make progress on key research and development milestones, including multiple next-generation product launches expected in the fourth quarter of this year, which we believe will bolster revenue growth.. Codex DNA is a public company based in San Diego. The archived webcast will remain available for replay on Codex DNAs website for 30 days. BioXp 3250 sales of 16 instruments, which was up 23% over the same period in the prior year. Codex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? For more information, visit codexdna.com. Vice President of Finance Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. For more information, visit codexdna.com.Contact:Richard LepkeDirector of Investor Relations(619) 840-5392RichardL@codexdna.com. Gross margin increased from 33.4% to 48.0%. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which is anticipated to be filed with the Securities and Exchange Commission on August 10, 2022. Codex DNA Reports First Quarter 2022 Financial Results - GlobeNewswire In conjunction with the release, management will host a conference call on Tuesday, March 22, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. Recent Highlights For more information, visit codexdna.com. Cash, cash equivalents and investments were $76.8 million as of March 31, 2022. 1001 and 1030). For the full year 2022, Codex DNA provided the following updated financial guidance: Webcast and Conference Call InformationCompany management will host a conference call today, August 9, 2022, at1:30 p.m. PDT/4:30 p.m. EDT to discuss the financial results and other recent corporate highlights. Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates The increase of $1.9 million was primarily driven by increased sales, resulting in higher raw material costs associated with reagents sales and biofoundry services, shipping and logistics costs, and increased personnel and departmental expenses. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. https://register.vevent.com/register/BI3c5895f666544e6abb6418b1b284105e, Cash, cash equivalents and short-term investments, Change in fair value of derivative liabilities, Weighted average common shares used to compute net loss per share, basic and diluted, Increased total revenue by 98% over prior year period, Grew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisition, Delivered solid growth in BioXp 3250 instrument placements, Experienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kits, Launched MyBioXperience, a new e-commerce solution, which dramatically simplifies and streamlines the customer ordering process for BioXp kits across DNA synthesis, cloning, libraries, and mRNA synthesis, Strengthened leadership team with the addition of Eric Esser as Chief Operating Officer, Progressing towards a fourth quarter 2022 launch of the higher-throughput BioXp 9600 instrument and production of an in-house oligo synthesis platform, Completed proof-of-concept demonstrations showing that Codex DNAs BioXp instrument can be used to effectively encode and retrieve digital data using DNA sequences, Advanced the SOLA enzymatic DNA synthesis (EDS) program to consistently and reliably generate oligos of 20 to 100 base pairs that are further assembled into genes, mRNA and protein on the BioXp instrument. Royalties and other revenue grew at 113% over second quarter 2021 due to revenue from the collaboration with Pfizer and continued growth of in-licensing royalties. By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically. Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. Codex DNA Reports Second Quarter 2022 Financial Results The award-winning BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Net loss was $13.2 million for the first quarter 2022, compared to $7.4 million in the same period in the prior year. Financial Ratios. Continued to execute in all areas of our growth strategy: Advanced our research and development programs: Webcast and Conference Call Information Net loss was $14.8 million for the second quarter 2022, compared to $9.2 million in the same period in the prior year. BioXp 3250 sales of 16 instruments, which was up 23% over the same period in the prior year. Codex Dna, Inc. (DNAY) 10-Q Quarterly Report August 2021 - Last10K.com | Source: Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Codex DNA Reports First Quarter 2022 Financial Results The award-winning BioXp system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. Codex DNA disclaims any obligation to update these forward-looking statements. About Codex DNACodex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanitys greatest challenges. Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday Codex DNA is a public company based in San Diego. Forward-Looking Statements Codex DNA, Inc. SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the market closes. Creators of the BioXp system, the worlds only fully automated gene synthesis platform, and the industry-standard Gibson Assembly method, Telesis Bio Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA. These statements include statements and guidance regarding Codex DNAs future financial performance as well as statements regarding the future release and success of products and services. About Codex DNACodex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanitys greatest challenges. Recent HighlightsContinued execution across all areas of the growth strategy: Key advancements on research and development (R&D) programs: I am pleased to share that this quarter we were able to once again deliver robust revenue growth across our product portfolio, said Todd R. Nelson, Ph.D., Codex DNAs Chief Executive Officer. This increase was driven by headcount expansion across our business, primarily in our commercial, research and development, and general and administrative organizations. Home Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex Dna, Inc. (DNAY) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022. May 10, 2022 16:05 ET Grew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisition. Financial Stability. Gross margin increased from 33.4% to 48.0%. The press release and live audio webcast can be accessed via the Investor section of Codex DNAs website at www.codexdna.com. Operating expenses in the range of $62 million to $65 million. Stockhouse.com is owned by Stockhouse Publishing Ltd. 2019 Stockhouse Publishing Ltd. All rights reserved. Codex Dna, Inc. (DNAY) 10-Q Quarterly Report Wed Nov 09 2022; SEC Filings. Cost of revenue for the first quarter 2022 was $2.9 million, compared to $1.0 million for the same period in the prior year. Codex DNA Reports Second Quarter 2022 Financial Results This press release contains forward-looking statements. SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop . Continued execution across all areas of the growth strategy: Key advancements on research and development (R&D) programs: I am pleased to share that this quarter we were able to once again deliver robust revenue growth across our product portfolio, said Todd R. Nelson, Ph.D., Codex DNAs Chief Executive Officer. CORRECTION -- Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Second Quarter Common Stock Procaps Group Reports First Quarter 2023 Results, Will 2023 be a Record-Breaking Year for Precious Metal Prices? General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. By using this site, you are agreeing to security monitoring and auditing. Please log in approximately 5-10 minutes before the event to ensure a timely connection. Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanitys greatest challenges. About Codex DNA We continue to make progress on key research and development milestones, including multiple next-generation product launches expected in the fourth quarter of this year, which we believe will bolster revenue growth.. Recent Highlights Continued to execute in all areas of our growth strategy: Increased total revenue by 142% over prior year period Grew revenue by 82% on an organic basis, excluding contributions. By providing my email, I consent to receiving investment related electronic messages from Stockhouse. Contact: Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Powered by Madgex Job Board Software, https://register.vevent.com/register/BI3c5895f666544e6abb6418b1b284105e, Cash, cash equivalents and short-term investments, Change in fair value of derivative liabilities, Weighted average common shares used to compute net loss per share, basic and diluted, Increased total revenue by 98% over prior year period, Grew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisition, Delivered solid growth in BioXp 3250 instrument placements, Experienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kits, Launched MyBioXperience, a new e-commerce solution, which dramatically simplifies and streamlines the customer ordering process for BioXp kits across DNA synthesis, cloning, libraries, and mRNA synthesis, Strengthened leadership team with the addition of Eric Esser as Chief Operating Officer, Progressing towards a fourth quarter 2022 launch of the higher-throughput BioXp 9600 instrument and production of an in-house oligo synthesis platform, Completed proof-of-concept demonstrations showing that Codex DNAs BioXp instrument can be used to effectively encode and retrieve digital data using DNA sequences, Advanced the SOLA enzymatic DNA synthesis (EDS) program to consistently and reliably generate oligos of 20 to 100 base pairs that are further assembled into genes, mRNA and protein on the BioXp instrument.
